Skip to content

Study · Animal study (in vivo) · rat · 2021

3 results

Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal.

Udovicic M, Sever M, Kavur L, Loncaric K, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D, Uzun S, Batelja Vuletic L, Sikiric S, Skrtic A and 5 more

Show all authors

Drmic D, Boban Blagaic A, Lovric Bencic M, Seiwerth S, Sikiric P

Biomedicines15 Jul 2021Cited by 21 (Europe PMC)

PMID34356886 (opens in a new tab)PMCIDPMC8301325 (opens in a new tab)DOI10.3390/biomedicines9070822 (opens in a new tab)PepBankPUB-34356886
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Background. Monocrotaline selectively injures the lung's vascular endothelium and induces pulmonary arterial hypertension. The stable gastric pentadecapeptide BPC 157 acts as a prototype cytoprotective agent that maintains endothelium, and its application may be a novel therapy. Besides, BPC 157 prevents and reverses thrombosis formation, maintains platelet function, alleviates peripheral vascular occlusion disturbances, and has anti-arrhythmic and anti-inflammatory effects. Monocrotaline-induced pulmonary arterial hypertension in rats (wall thickness, total vessel area, heart frequency, QRS axis deviation, QT interval prolongation, increase in right ventricle systolic pressure and bodyweight loss) can be counteracted with early or delayed BPC 157 therapy. Methods and Results. After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1-14 or days 1-30 (early regimens), or days 14-30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30). Without therapy, the outcome was the full monocrotaline syndrome, marked by right-side heart hypertrophy and massive thickening of the precapillary artery's smooth muscle layer, clinical deterioration, and sometimes death due to pulmonary hypertension and right-heart failure during the 4th week after monocrotaline injection. With all BPC 157 regimens, monocrotaline-induced pulmonary arterial hypertension (including all disturbed parameters) was counteracted, and consistent beneficial effects were documented during the whole course of the disease. Pulmonary hypertension was not even developed (early regimens) as quickly as the advanced pulmonary hypertension was rapidly attenuated and then completely eliminated (delayed regimen). Conclusions. Thus, pentadecapeptide BPC 157 prevents and counteracts monocrotaline-induced pulmonary arterial hypertension and cor pulmonale in rats.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given monocrotaline, all BPC‑157 regimens counteracted pulmonary arterial hypertension, including all disturbed parameters.

    In plain wordsIn rats with induced lung artery high blood pressure, every BPC‑157 schedule counteracted the condition compared with no therapy.

    Peptide
    BPC-157
    Outcome
    DecreaseMonocrotaline-induced pulmonary arterial hypertension, all regimens
    Study

    ratn: not reported in source

    Monocrotaline-induced pulmonary arterial hypertension
    Comparator
    Monocrotaline without BPC 157 therapy
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg/kg or 10 ng/kg · intraperitoneal once daily, or continuously in drinking water · days 1-14, 1-30 or 14-30As given in this study (rat).

    Source sentences

    Summary
    With all BPC 157 regimens, monocrotaline-induced pulmonary arterial hypertension (including all disturbed parameters) was counteracted, and consistent beneficial effects were documented during the whole course of the disease.
    1 context sentence
    Summary · context
    After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1-14 or days 1-30 (early regimens), or days 14-30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given monocrotaline, early BPC‑157 regimens prevented the development of pulmonary hypertension.

    In plain wordsIn rats, BPC‑157 started early stopped lung artery high blood pressure from developing.

    Peptide
    BPC-157
    Outcome
    DecreaseDevelopment of pulmonary hypertension, early regimens (prevention)
    Study

    ratn: not reported in source

    Monocrotaline-induced pulmonary arterial hypertension
    Comparator
    Monocrotaline without BPC 157 therapy
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg/kg or 10 ng/kg · intraperitoneal once daily, or continuously in drinking water · days 1-14 or 1-30As given in this study (rat).

    Source sentences

    Summary
    Pulmonary hypertension was not even developed (early regimens)
    1 context sentence
    Summary · context
    After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1-14 or days 1-30 (early regimens), or days 14-30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given monocrotaline, delayed BPC‑157 therapy rapidly attenuated advanced pulmonary hypertension and then completely eliminated it.

    In plain wordsIn rats, BPC‑157 started late reversed advanced lung artery high blood pressure.

    Peptide
    BPC-157
    Outcome
    DecreaseAdvanced pulmonary hypertension, delayed regimen (reversal)
    Study

    ratn: not reported in source

    Monocrotaline-induced pulmonary arterial hypertension
    Comparator
    Monocrotaline without BPC 157 therapy
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg/kg or 10 ng/kg · intraperitoneal once daily, or continuously in drinking water · days 14-30As given in this study (rat).

    Source sentences

    Summary
    as quickly as the advanced pulmonary hypertension was rapidly attenuated and then completely eliminated (delayed regimen).
    1 context sentence
    Summary · context
    After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1-14 or days 1-30 (early regimens), or days 14-30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.